(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 18 September 2003 (18.09.2003)

PCT

(10) International Publication Number WO 2003/076472 A3

- (51) International Patent Classification⁷: C07K 16/30, C12N 5/28, 15/08, G01N 33/574, 33/577, A61K 51/10, 39/395, 47/48, A61P 35/00
- (21) International Application Number:

PCT/IB2003/001335

- (22) International Filing Date: 10 March 2003 (10.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

102 10 427.1

9 March 2002 (09.03.2002) DE

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US Filed on 102 10 427.1 (CIP) 8 March 2002 (08.03.2002)

(71) Applicant (for all designated States except US):
ONCOMAB GMBH [DE/DE]; c/o IGZ BioMed,
Friedrich-Bergius-Ring 15, 97076 Würzburg (DE).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): VOLLMERS, Heinz, Peter [DE/DE]; Budapeststrasse 23, 97084 Würzburg (DE). MUELLER-HERMELINK, Hans, Konrad [DE/DE]; Heinrich-Zeuner-Strasse, 97082 Würzburg (DE).

- (74) Agents: WEICKMANN, F., A. et al.; Weickmann & Weickmann, Postfach 860 820, 81635 München (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BI, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description
- (88) Date of publication of the international search report: 25 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF

(57) Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.

International ition No PCT/IB 03/01335

CLASSIFICATION OF SUBJECT MATTER PC 7 CO7K16/30 C12N C12N5/28 G01N33/574 C12N15/08 G01N33/577 A61K51/10 A61K39/395 A61K47/48 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, SEQUENCE SEARCH, WPI Data, PAJ, MEDLINE, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to daim No. X WO 01 83560 A (ICHIKAWA KIMIHISA :KIMBERLY 1-6,13,ROBERT P (US); KOOPMAN WILLIAM J (US);) 14, 8 November 2001 (2001-11-08) 17-20, 26-53 abstract page 1, line 25 - line 31 page 3, line 7 - line 9 page 4, line 25 - line 28 page 5, line 20 - line 30 page 5, line 22 - line 25 page 6, line 3 - line 5 page 6, line 25 - line 27 page 12, line 18 - line 31 page 20, line 1 - line 8 page 29, line 27 - line 28 page 30, line 17 - line 29 page 35, line 6 - line 11 page 36, line 15 - line 17 page 58, line 1 - line 2 Further documents are listed in the continuation of box C. X X Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the International "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an Inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the International search Date of mailing of the international search report 3 November 2003 28/11/2003 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Irion, A

Fax: (+31-70) 340-3016

Internations ation No

	INTERNATIONAL SEARCH REPORT	PCT/IB 03/01335	
(Continua	ntlon) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
and a	, and manager, mile of appropriate, or the relevant passages	neevall to claim NO.	
(WO 97 13844 A (CAMBRIDGE ANTIBODY TECH; TEMPEST PHILIP RONALD (GB); THOMSON JULIA) 17 April 1997 (1997-04-17) figures 1,2,19 page 17, line 25 -page 18, line 21 page 1, line 8 - line 11 page 38, line 6 - line 9 page 38, line 16 - line 20 claims 1-34	9,12-16, 21,22, 26,52,53	
(WO 01 62932 A (AMGEN INC) 30 August 2001 (2001-08-30) claim 9	23,26	
(EP 1 106 183 A (GENENTECH INC ;REGENTS BOARD OF (US)) 13 June 2001 (2001-06-13)	3,6, 12-14, 16, 29-33, 36-41, 44-49, 52,53	
	page 9, line 23 - line 30 page 17, line 15 - line 24 page 24, line 46 - line 55 page 5, line 5 - line 7 page 10, line 38 - line 44 page 14, line 26 - line 34	52,53	
	BRAENDLEIN STEPHANIE ET AL: "Characterization of five new fully human monoclonal IgM antibodies isolated from carcinoma patients" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-03), page 970 XP001155782 93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA; April 06-10, 2002, March, 2002 ISSN: 0197-016X the whole document	1-53	
	BRAENDLEIN STEPHANIE ET AL: "Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients." HUMAN ANTIBODIES, vol. 11, no. 4, 2002, pages 107-119, XP009020163	1-53	

Internation stion No
PCT/IB 03/01335

		PCI/IB US	, 01000	
C.(Continu	etion) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
A	MENG RAYMOND D ET AL: "p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma" EXPERIMENTAL CELL RESEARCH, vol. 262, no. 2, 15 January 2001 (2001-01-15), pages 154-169, XP002260126 ISSN: 0014-4827 the whole document		1-53	
Α	HUANG YING ET AL: "Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells" CANCER RESEARCH, vol. 61, no. 18, 15 September 2001 (2001-09-15), pages 6918-6924, XP002260127 ISSN: 0008-5472 the whole document		1-53	
		•		
	•			

International application No. PCT/IB 03/01335

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 36-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT Information on patent family members

Internationa ... ation No PCT/IB 03/01335

				101/10	03/01335
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0183560	A	08-11-2001	AU CA CN CZ EP NO WO	5936601 A 2407965 A1 1440424 T 20023917 A3 1287035 A1 20025253 A 0183560 A1	12-11-2001 08-11-2001 03-09-2003 14-05-2003 05-03-2003 18-12-2002 08-11-2001
WO 9713844	A	17-04-1997	AT AT AU CA DE DE DE DE EP ES WO GB GR GR JP PT	190650 T 199091 T 702049 B2 7140596 A 2233042 A1 69607191 D1 69607191 T2 69611766 D1 69611766 T2 945464 T3 0853661 A1 0945464 A1 2146020 T3 2156035 T3 9713844 A1 2305921 A ,B 3033436 T3 3035775 T3 2000500643 T 853661 T 945464 T	15-04-2000 15-02-2001 11-02-1999 30-04-1997 17-04-1997 20-04-2000 28-09-2000 15-03-2001 02-08-2001 07-05-2001 22-07-1998 29-09-1999 16-07-2000 01-06-2001 17-04-1997 23-04-1997 23-04-1997 29-09-2000 31-07-2001 25-01-2000 31-07-2001
WO 0162932	A	30-08-2001	US AU CA EP JP WO	2003103978 A1 3868001 A 2400929 A1 1257648 A1 2003523772 T 0162932 A1	05-06-2003 03-09-2001 30-08-2001 20-11-2002 12-08-2003 30-08-2001
EP 1106183	А	13-06-2001	EP AU BR CN EP JP KR TR WO ZA	1106183 A2 4982097 A 9712410 A 1234072 A 0931147 A1 2001504326 T 2001302540 A 2000049261 A 9901615 T2 9817797 A1 9709185 A	13-06-2001 15-05-1998 19-10-1999 03-11-1999 28-07-1999 03-04-2001 31-10-2001 25-07-2000 22-11-1999 30-04-1998 14-04-1999